» Articles » PMID: 35538051

Statin Therapy Inhibits Fatty Acid Synthase Via Dynamic Protein Modifications

Abstract

Statins are a class of drug widely prescribed for the prevention of cardiovascular disease, with pleiotropic cellular effects. Statins inhibit HMG-CoA reductase (HMGCR), which converts the metabolite HMG-CoA into mevalonate. Recent discoveries have shown HMG-CoA is a reactive metabolite that can non-enzymatically modify proteins and impact their activity. Therefore, we predicted that inhibition of HMGCR by statins might increase HMG-CoA levels and protein modifications. Upon statin treatment, we observe a strong increase in HMG-CoA levels and modification of only a single protein. Mass spectrometry identifies this protein as fatty acid synthase (FAS), which is modified on active site residues and, importantly, on non-lysine side-chains. The dynamic modifications occur only on a sub-pool of FAS that is located near HMGCR and alters cellular signaling around the ER and Golgi. These results uncover communication between cholesterol and lipid biosynthesis by the substrate of one pathway inhibiting another in a rapid and reversible manner.

Citing Articles

Evaluating the implementation of inclisiran in primary care: process evaluation interim findings from interviews with key stakeholders.

Wilson P, Elvey R, Mathieson A, Bower P, Gibson M, Vell T BMJ Open. 2025; 15(2):e083441.

PMID: 40010816 PMC: 11865805. DOI: 10.1136/bmjopen-2023-083441.


Cysteine -acetylation is a post-translational modification involved in metabolic regulation.

Keenan E, Bareja A, Lam Y, Grimsrud P, Hirschey M bioRxiv. 2024; .

PMID: 38826225 PMC: 11142221. DOI: 10.1101/2024.05.21.595030.


mTORC1-CTLH E3 ligase regulates the degradation of HMG-CoA synthase 1 through the Pro/N-degron pathway.

Yi S, Sepic S, Schulman B, Ordureau A, An H Mol Cell. 2024; 84(11):2166-2184.e9.

PMID: 38788716 PMC: 11186538. DOI: 10.1016/j.molcel.2024.04.026.


Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update.

Luca F, Oliva F, Rao C, Abrignani M, Amico A, Di Fusco S Metabolites. 2023; 13(8).

PMID: 37623860 PMC: 10456563. DOI: 10.3390/metabo13080916.


Atomic model for core modifying region of human fatty acid synthase in complex with Denifanstat.

Hasan S, Lou J, Keszei A, Dai D, Mazhab-Jafari M Nat Commun. 2023; 14(1):3460.

PMID: 37308485 PMC: 10258763. DOI: 10.1038/s41467-023-39266-y.


References
1.
Leighty R, Antoniewicz M . COMPLETE-MFA: complementary parallel labeling experiments technique for metabolic flux analysis. Metab Eng. 2013; 20:49-55. DOI: 10.1016/j.ymben.2013.08.006. View

2.
Kumai T, Matsumoto N, Koitabashi Y, Takeba Y, Oonuma S, Sekine S . Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels. Curr Med Chem Cardiovasc Hematol Agents. 2005; 3(3):195-201. DOI: 10.2174/1568016054368223. View

3.
Funai K, Song H, Yin L, Lodhi I, Wei X, Yoshino J . Muscle lipogenesis balances insulin sensitivity and strength through calcium signaling. J Clin Invest. 2013; 123(3):1229-40. PMC: 3582136. DOI: 10.1172/JCI65726. View

4.
Antoniewicz M, Kelleher J, Stephanopoulos G . Elementary metabolite units (EMU): a novel framework for modeling isotopic distributions. Metab Eng. 2006; 9(1):68-86. PMC: 1994654. DOI: 10.1016/j.ymben.2006.09.001. View

5.
. The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Res. 2020; 49(D1):D325-D334. PMC: 7779012. DOI: 10.1093/nar/gkaa1113. View